72.08
price down icon1.21%   -0.88
after-market アフターアワーズ: 72.23 0.15 +0.21%
loading
前日終値:
$72.96
開ける:
$73.65
24時間の取引高:
1.02M
Relative Volume:
0.95
時価総額:
$2.07B
収益:
$55.23M
当期純損益:
$-164.08M
株価収益率:
-10.53
EPS:
-6.8461
ネットキャッシュフロー:
$-208.68M
1週間 パフォーマンス:
-1.50%
1か月 パフォーマンス:
+2.43%
6か月 パフォーマンス:
+29.59%
1年 パフォーマンス:
+8,509%
1日の値動き範囲:
Value
$70.86
$77.97
1週間の範囲:
Value
$70.67
$77.97
52週間の値動き範囲:
Value
$0.432
$77.97

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1114)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
72.08 2.09B 55.23M -164.08M -208.68M -6.8461
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
05:10 AM

Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

05:10 AM
pulisher
11:15 AM

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph

11:15 AM
pulisher
10:45 AM

Nektar Therapeutics stock hits 52-week high at 77.36 USD By Investing.com - Investing.com Australia

10:45 AM
pulisher
10:02 AM

Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighHere's Why - MarketBeat

10:02 AM
pulisher
09:02 AM

NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com

09:02 AM
pulisher
03:03 AM

Wedbush initiates coverage of Nektar Therapeutics (NKTR) with neutral recommendation - MSN

03:03 AM
pulisher
Mar 24, 2026

Wedbush Initiates Coverage on Nektar Therapeutics (NKTR) with Ne - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.

Mar 24, 2026
pulisher
Mar 24, 2026

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures - TipRanks

Mar 24, 2026
pulisher
Mar 24, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Wedbush - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit — The Gross Law Firm - Morningstar

Mar 24, 2026
pulisher
Mar 24, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Wedbush initiates Nektar Therapeutics stock with neutral rating By Investing.com - Investing.com Australia

Mar 24, 2026
pulisher
Mar 24, 2026

Wedbush initiates Nektar Therapeutics stock with neutral rating - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Wedbush Starts Nektar Therapeutics (NKTR) at Neutral - StreetInsider

Mar 24, 2026
pulisher
Mar 23, 2026

Nektar Therapeutics Faces High-Stakes AAD Data Test as Sky-High Valuation Leaves Little Room for Error - Bitget

Mar 23, 2026
pulisher
Mar 23, 2026

A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting - simplywall.st

Mar 23, 2026
pulisher
Mar 23, 2026

Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action - PR Newswire

Mar 23, 2026
pulisher
Mar 23, 2026

NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire

Mar 23, 2026
pulisher
Mar 23, 2026

Nektar Therapeutics stock is trending Tuesday: What's going on? - MSN

Mar 23, 2026
pulisher
Mar 23, 2026

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire

Mar 23, 2026
pulisher
Mar 23, 2026

Apogee strengthens case for longer-lasting eczema drug - BioPharma Dive

Mar 23, 2026
pulisher
Mar 23, 2026

Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections - statnews.com

Mar 23, 2026
pulisher
Mar 23, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph

Mar 23, 2026
pulisher
Mar 23, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Mar 23, 2026
pulisher
Mar 21, 2026

2 Healthcare Stocks to Buy Before They Get Bought Out - AOL.com

Mar 21, 2026
pulisher
Mar 21, 2026

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire

Mar 21, 2026
pulisher
Mar 21, 2026

NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com

Mar 21, 2026
pulisher
Mar 21, 2026

Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR - MarketBeat

Mar 21, 2026
pulisher
Mar 21, 2026

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Mar 21, 2026
pulisher
Mar 21, 2026

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire

Mar 21, 2026
pulisher
Mar 21, 2026

Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN

Mar 21, 2026
pulisher
Mar 20, 2026

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The AI Journal

Mar 20, 2026
pulisher
Mar 20, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm - WFXG

Mar 20, 2026
pulisher
Mar 20, 2026

Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 20, 2026
pulisher
Mar 20, 2026

Two skin and hair-loss studies from Nektar get oral AAD slots - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Abivax & Nektar Therapeutics: Clinical-Stage Biotech Drug Development in 2026News and Statistics - IndexBox

Mar 20, 2026
pulisher
Mar 20, 2026

2 Healthcare Shares to Consider Purchasing Before Potential Buyouts - Bitget

Mar 20, 2026
pulisher
Mar 20, 2026

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting - Sahm

Mar 20, 2026
pulisher
Mar 19, 2026

NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 19, 2026
pulisher
Mar 19, 2026

How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates - Yahoo Finance

Mar 19, 2026
pulisher
Mar 19, 2026

B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With 295+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart

Mar 19, 2026
pulisher
Mar 19, 2026

ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics - GlobeNewswire

Mar 19, 2026
pulisher
Mar 19, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire

Mar 19, 2026
pulisher
Mar 19, 2026

NKTR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile

Mar 19, 2026
pulisher
Mar 19, 2026

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire

Mar 19, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):